- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Polycythemia vera (PV)
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2025 PBAC Meeting - (Word)
Ruxolitinib – March 2025
Ruxolitinib; Tablet 5 mg, Tablet 10 mg, Tablet 15 mg, Tablet 20 mg; Jakavi®
Last updated
12 March 2025